3. (Unchanged) The method of claim 2, further comprising purifying sIg from the supernatant.

4. (Amended) The method of claim 1, wherein the secretory Ig and SC are derived from the same species of organism.

A2

5. (Amended) The method of claim 1, wherein the secretory Ig and SC are derived from different species of organism.

6. (Amended) The method of claim 1, wherein the SC comprises the amino acid sequence shown in SEQ ID NO:4 or a congener thereof capable of associating with an Ig molecule.

7. (Unchanged) The method of claim 1, wherein the cell endogenously produces Ig.

8. (Unchanged) The method of claim 1, wherein the cell is genetically modified to produce Ig.

9. (Unchanged) The method of claim 1, wherein the cell is a mammalian, avian, insect, bacterial or yeast cell.

10. (Unchanged) The method of claim 9, wherein the mammalian cell is a human, rabbit, murine, rat or bovine cell.

11. (Unchanged) The method of claim 1, wherein the cell is a myeloma cell, CHO cell, L cell, COS cell, fibroblast, MDCK cell, HT29 cell or a T84 cell.

12. (Unchanged) The method of claim 1, wherein the Ig molecule is an IgA.

13. (Unchanged) The method of claim 1, wherein the Ig molecule is a domain-modified IgA.

14. (Unchanged) A secretory IgA produced by the method of claim 1.

15. (Unchanged) A pharmaceutical composition comprising the secretory IgA of claim 14 and a pharmaceutically acceptable carrier.